Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 3/2016

01-03-2016 | Original Article

Deregulation of miR-93 and miR-143 in human esophageal cancer

Authors: Mohammad Hossein Ansari, Shiva Irani, Houri Edalat, Ruhul Amin, Amaneh Mohammadi Roushandeh

Published in: Tumor Biology | Issue 3/2016

Login to get access

Abstract

Esophageal squamous cell carcinoma (ESCC) is the second and third most common malignancy in Iranian males and females, respectively. Treatment of ESCC is largely ineffective due to lack of detection at early stages of the disease. In recent years, miRNA, a small RNA molecule, has drawn much attention to researchers as a potential biomarker for esophageal cancer. miR-93 and miR-143 are two miRNA molecules reported to be frequently deregulated in various cancers, including prostate, stomach, cervix, and etc. The purpose of this study was to investigate the expression levels of these miRNAs and evaluate their diagnostic and therapeutic potential in esophageal squamous cell carcinoma. In this study, total RNA was extracted from 30 tumor tissues and 30 nontumor tissues of esophageal tumor margins, using RNX-plus solution. After validating the quality and quantity of total RNA, cDNAs of interest were synthesized using microRNA-specific cDNA Synthesis Kit. The expression level of miR-93 and miR-143 was evaluated using quantitative real-time PCR with miRNA-specific primers. Finally, the obtained data was analyzed by SPSS ver.20 software and paired t test was performed to observe the significance of difference between groups. The expression level of miR-93 was significantly increased and of miR-143 was significantly decreased in most of the examined tumor tissues, compared to nontumor tissues. Also, our findings did not detect correlation between mir-93 and mir-143 expressions in regard to stage and grade of the samples. These findings suggest that the deregulation of these miRNAs may play an important role in esophageal squamous cell carcinoma. Both miR-93 and miR-143 might be used as potential biomarkers in esophageal squamous cell carcinoma. However, more studies with large population of samples are necessary.
Literature
1.
2.
3.
Thai T-H, Christiansen PA, Tsokos GC. Is there a link between dysregulated miRNA expression and disease? Discov Med. 2010;10(52):184–94.PubMed
4.
Roush SF, Slack FJ. Micromanagement: a role for microRNAs in mRNA stability. ACS Chem Biol. 2006;1(3):132–4.CrossRefPubMed
5.
6.
Vasudevan S. Posttranscriptional upregulation by microRNAs. Wiley Interdisciplinary Reviews: RNA. 2012;3(3):311–30.CrossRefPubMed
7.
8.
Calin GA et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101(9):2999–3004.CrossRefPubMedPubMedCentral
9.
10.
Jay C, Nemunaitis J, Chen P, Fulgham P, Tong AW. miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol. 2007;26(5):293–300.
11.
Tricoli JV, Jacobson JW. MicroRNA: potential for cancer detection, diagnosis, and prognosis. Cancer Res. 2007;67(10):4553–5.CrossRefPubMed
12.
Chiam K, et al. Circulating serum exosomal miRNAs as potential biomarkers for esophageal adenocarcinoma. J. Gastrointest. Surg. 2015:19(7):1208–15.
13.
14.
Raponi M et al. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res. 2009;69(14):5776–83.CrossRefPubMed
15.
Wang F, Zheng Z, Guo J, Ding X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol. 2010;119(3):586–93.
16.
17.
Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol. 2010;42(8):1273–81.CrossRefPubMed
18.
19.
Wszolek MF, et al. A MicroRNA expression profile defining the invasive bladder tumor phenotype. In Urologic Oncology: Seminars and Original Investigations. 2011;29(6):794–801.
20.
Gao W, Yu Y, Cao H, Shen H, Li X, Pan S, Shu Y. Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother. 2010;64(6):399–408.
21.
Vychytilova-Faltejskova P et al. MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma. Diagn Pathol. 2015;10(1):38.CrossRefPubMedPubMedCentral
22.
23.
24.
25.
Nie J, et al. miR-34a inhibits the migration and invasion of esophageal squamous cell carcinoma by targeting Yin Yang-1. Oncol. Rep. 2015;34(1):311–7.
26.
Pagliuca A et al. Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene. 2013;32(40):4806–13.CrossRefPubMed
27.
Schou JV et al. miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan. PLoS One. 2014;9(6):e99886.CrossRefPubMedPubMedCentral
28.
29.
Xu B et al. miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS. Mol Cell Biochem. 2011;350(1–2):207–13.CrossRefPubMed
30.
Noguchi S et al. MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. Cancer Lett. 2011;307(2):211–20.CrossRefPubMed
31.
Chen X et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene. 2009;28(10):1385–92.CrossRefPubMed
32.
Cho WC. MicroRNAs in cancer—from research to therapy. Biochim Biophys Acta, Biophys Incl Photsynth Rev Can. 2010;1805(2):209–17.
33.
Kojima S et al. The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer. J Hum Genet. 2014;59(2):78–87.CrossRefPubMed
34.
Goto Y, Kurozumi A, Enokida H, Ichikawa T, Seki N. Functional significance of aberrantly expressed microRNAs in prostate cancer. Int. J. Urol. 2015;22(3):242–52
35.
Clapé C, et al. miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PLos One. 2009;26;4(10):e7542.
36.
37.
Lin S-L, Ying S-Y. Gene silencing in vitro and in vivo using intronic microRNAs, in MicroRNA. Protocols. 2013;342:295–312.
38.
39.
40.
Petrocca F et al. E2F1-regulated microRNAs impair TGFβ-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell. 2008;13(3):272–86.CrossRefPubMed
41.
Yu D, Shin HS, Lee YS, Lee YC. miR-106b modulates cancer stem cell characteristics through TGF-β/Smad signaling in CD44-positive gastric cancer cells. Lab. Investig. 2014;94(12):1370–81.
42.
43.
Zheng S, Vuitton L, Sheyhidin I, Vuitton DA, Zhang Y, Lu X. Northwestern China: a place to learn more on oesophageal cancer. Part one: behavioural and environmental risk factors. Eur J Gastroenterol Hepatol. 2010;22(8):917–25.
44.
45.
Kamangar F, Malekzadeh R, Dawsey SM, Saidi F. Esophageal cancer in Northeastern Iran: a review. Arch Iran Med. 2007;10(1):70–82.
46.
Sadjadi A, Marjani H, Semnani SH, Nasseri-Moghaddam S. Esophageal cancer in Iran: a review. Middle East J Cancer. 2010;1(1):5–14.
47.
Zehetner J et al. Endoscopic resection and ablation versus esophagectomy for high-grade dysplasia and intramucosal adenocarcinoma. J Thorac Cardiovasc Surg. 2011;141(1):39–47.CrossRefPubMed
48.
49.
Roth MJ et al. Cytologic detection of esophageal squamous cell carcinoma and precursor lesions using balloon and sponge samplers in asymptomatic adults in Linxian. China Cancer. 1997;80(11):2047–59.CrossRefPubMed
50.
51.
Stewart BW, Kleihues P, I.A.f.R.o. Cancer. World cancer report. Vol. 57. Lyon: IARC press; 2003.
52.
Nie J, et al. miR-34a inhibits the migration and invasion of esophageal squamous cell carcinoma by targeting Yin Yang-1. Oncol. Rep. 2015;34(1):311–7.
53.
Ilhan-Mutlu A, et al. microRNA-21 Expression is elevated in esophageal adenocarcinoma after neoadjuvant chemotherapy. Cancer Investig. 2015;33(6):246–50.
54.
Feber A et al. MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg. 2008;135(2):255–60.CrossRefPubMed
55.
Li G et al. Increased expression of miR-93 is associated with poor prognosis in head and neck squamous cell carcinoma. Tumor Biol. 2015;36(5):3949–56.CrossRef
56.
57.
Liu L et al. miR-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2. Mol Med Rep. 2012;5(3):753–60.PubMed
58.
Kano M et al. miR‐145, miR‐133a and miR‐133b: tumor‐suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer. 2010;127(12):2804–14.CrossRefPubMed
59.
Gu J, Wang Y, Wu X. MicroRNA in the pathogenesis and prognosis of esophageal cancer. Curr Pharm Des. 2013;19(7):1292–300.PubMed
60.
Zhang H, Cai X, Wang Y, Tang H, Tong D, Ji F. microRNA-143, down-regulated in osteosarcoma, promotes apoptosis and suppresses tumorigenicity by targeting Bcl-2. Oncol Rep. 2010;24(5):1363–9.
61.
Zhang J, Sun Q, Zhang Z, Ge S, Han ZG, Chen WT. Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop. Oncogene. 2013;32(1):61–9.
62.
Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer. 1994;69(1):135.
63.
Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res. 1994;54(8):2095–7.
64.
65.
66.
Mattie MD et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer. 2006;5(1):24.CrossRefPubMedPubMedCentral
67.
Luthra R et al. MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers. Oncogene. 2008;27(52):6667–78.CrossRefPubMed
68.
Maru DM et al. MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus. Am J Pathol. 2009;174(5):1940–8.CrossRefPubMedPubMedCentral
69.
Lardizábal MN et al. Reference genes for real-time PCR quantification of microRNAs and messenger RNAs in rat models of hepatotoxicity. PLoS One. 2012;7(5):e36323.CrossRefPubMedPubMedCentral
Metadata
Title
Deregulation of miR-93 and miR-143 in human esophageal cancer
Authors
Mohammad Hossein Ansari
Shiva Irani
Houri Edalat
Ruhul Amin
Amaneh Mohammadi Roushandeh
Publication date
01-03-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 3/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3987-9

Other articles of this Issue 3/2016

Tumor Biology 3/2016 Go to the issue

Original Article

ROBO1 deletion as a novel germline alteration in breast and colorectal cancer patients

Original Article

Long noncoding RNA PVT1 modulates thyroid cancer cell proliferation by recruiting EZH2 and regulating thyroid-stimulating hormone receptor (TSHR)

Original Article

PI-88 inhibits postoperative recurrence of hepatocellular carcinoma via disrupting the surge of heparanase after liver resection

Original Article

Immunophenotyping of patients with oral squamous cell carcinoma in peripheral blood and associated tumor tissue

Original Article

The long non-coding RNA HOTAIR affects the radiosensitivity of pancreatic ductal adenocarcinoma by regulating the expression of Wnt inhibitory factor 1

Original Article

FGF18 as a potential biomarker in serous and mucinous ovarian tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits